(MENAFN- Straits Research)
Colloids (Blood Plasma) Market Size, Share & Growth Analysis
The global colloids market size was valued at USD 3.61 billion in 2025 and is projected to grow from USD 3.80 billion in 2026 to USD 5.75 billion by 2034, registering a CAGR of 5.3% during the forecast period from 2026 to 2034. North America dominated the colloids market with a market share of 38.4% in 2025.
Colloids refer to substances dispersed evenly in another substance. In the context of blood plasma, colloids are primarily proteins such as albumin, globulins, and fibrinogen. These proteins contribute to the osmotic pressure of blood, helping to maintain fluid balance between blood vessels and tissues. Albumin, the most abundant plasma protein, assists in transporting hormones, fatty acids, and drugs, while globulins play a critical role in immune function by carrying antibodies.
Colloids (Blood Plasma) Market Key Takeaways
Global Market Size & Growth
2025 Market Size: USD 3.61 Billion
2026 Market Size: USD 3.80 Billion
2034 Projected Market Size: USD 5.75 Billion
Forecast Period: 2026–2034
Base Year: 2025
Market CAGR (2026–2034): 5.3%
Regional Insights
Largest Regional Market (2025): North America
North America Market Share (2025): 39.2%
Fastest-Growing Region: Asia-Pacific
Asia-Pacific CAGR (2026–2034): 8.12%
Segment Insights
By Type
Leading Segment: Natural Type Colloids
Market Share in 2025: 63.7%
By Applications
Fastest-growing segment: Hypovolemic Shock
CAGR: 7.18% (2026-2034)
Download a Free Sample To learn more about this report,
Colloids (Blood Plasma) Market Trends
Growing Adoption of Plasma-Derived Therapies and Albumin for Critical Care
The colloids (blood plasma) market trends are increasingly driven by the growing use of plasma-derived products, particularly human albumin, in critical care, trauma, liver disease, and intensive care units (ICUs). Albumin remains one of the most widely used natural colloid solutions for maintaining blood volume in patients with severe burns, shock, sepsis, and major surgeries. Rising demand for plasma-derived medicinal products (PDMPs), coupled with increasing plasma collection and fractionation capacity, is supporting market growth. According to the World Health Organization (WHO), plasma-derived therapies are considered essential medicines for treating several life-threatening conditions, encouraging countries to strengthen plasma collection and manufacturing capabilities.
For instance, in 2025, Grifols expanded its plasma collection network in the United States and increased investments in plasma fractionation capacity to meet the growing global demand for albumin and other plasma-derived therapies. The expansion is expected to improve the availability of critical plasma products used in hospitals and emergency care, reinforcing colloids (blood plasma) market trends.
Rising Investments in Plasma Collection and Blood Supply Infrastructure
The colloids (blood plasma) market is witnessing steady growth due to increasing investments in blood collection infrastructure and plasma donation programs. The growing prevalence of chronic diseases, surgical procedures, and immune-related disorders is further increasing the need for plasma-derived colloid products in healthcare settings.
For instance, in March 2025, CSL Behring announced the expansion of its global plasma collection network through its CSL Plasma business, increasing donor capacity and strengthening the supply chain for plasma-derived medicinal products, including human albumin and immunoglobulins. These developments are reinforcing the colloids (blood plasma) market growth and supporting the long-term expansion of the global market.
Colloids (Blood Plasma) Market Dynamics
Market Drivers
Rising Demand for Critical Care and Trauma Management
The colloids (blood plasma) market growth is driven by the increasing demand for effective volume replacement therapies in critical care, trauma, emergency medicine, and major surgical procedures. Colloid solutions are widely used to restore blood volume, stabilize blood pressure, and maintain tissue perfusion in patients experiencing severe blood loss, burns, septic shock, and hypovolemia. The growing number of surgical procedures, rising incidence of road accidents, and increasing prevalence of chronic diseases requiring intensive care are further supporting market growth. The colloids (blood plasma) market growth is also fueled by expanding healthcare infrastructure, improved emergency medical services, and continuous advancements in plasma-derived therapies and critical care management.
Market Restraints
Safety Concerns and Stringent Regulatory Requirements
The colloids (blood plasma) market faces significant restraints due to concerns regarding adverse reactions, coagulation disorders, kidney-related complications associated with certain synthetic colloids, and the risk of allergic responses. Regulatory authorities have introduced stricter guidelines governing the clinical use of specific colloid solutions, particularly hydroxyethyl starch products, limiting their application in certain patient populations. The colloids (blood plasma) market analysis also indicates that high manufacturing costs, complex plasma collection processes, and strict quality control requirements increase production expenses. In addition, the limited availability of plasma donations in some regions continues to challenge market expansion.
Market Opportunities
Growth in Plasma Fractionation and Advanced Critical Care Therapies
The increasing demand for plasma-derived therapeutics and advancements in plasma fractionation technologies are creating significant opportunities for the colloids (blood plasma) market. The colloids (blood plasma) market analysis highlights growing applications in intensive care units, emergency medicine, liver disease management, and complex surgical procedures. Rising healthcare investments, expanding hospital infrastructure, and increasing demand for advanced biologics are expected to create long-term growth opportunities for market participants.
Market Challenges
Ensuring Plasma Supply and Maintaining Product Safety
One of the major challenges facing the colloids (blood plasma) market is maintaining a stable supply of high-quality plasma while ensuring stringent safety standards throughout collection, processing, and distribution. The colloids (blood plasma) market growth is also affected by increasing production costs, evolving clinical guidelines, and the need for continuous monitoring of product efficacy and safety. Balancing growing clinical demand with sustainable plasma collection, regulatory compliance, and cost-effective manufacturing remains a key challenge for companies operating in the global colloids (blood plasma) market.
Colloids (Blood Plasma) Market Segmentation
By Type
Natural Type Colloids Dominated the Market with 63.7% Share in 2025
The natural type colloids segment accounted for the largest share of the global colloids (blood plasma) market at 63.7% in 2025, driven by their superior biocompatibility, effective plasma volume expansion, and widespread use in critical care, trauma management, and surgical procedures.
Synthetic type colloids continue to witness steady demand due to their cost-effectiveness, longer shelf life, and availability for rapid fluid resuscitation. They are commonly used in emergency medicine and perioperative care where immediate restoration of blood volume is required.
Request Customization to receive a tailored report.
By Applications
Hypovolemic Shock is Projected to Register the Fastest Growth at a CAGR of 7.18%
The hypovolemic shock segment is expected to expand at the highest CAGR of 7.18% during 2026–2034, supported by the rising incidence of trauma, severe dehydration, surgical complications, and emergency conditions requiring rapid plasma volume replacement.
Massive blood or plasma loss remains a major application area owing to the increasing number of surgical procedures, accident-related injuries, and hemorrhagic emergencies requiring effective volume expansion. Extensive burns continue to drive demand for colloid solutions to maintain circulatory stability and support fluid management in burn patients. Other applications, including critical care and postoperative fluid therapy, are also contributing to the sustained adoption of blood plasma colloids across healthcare settings.
Speak to an Analyst to discuss market opportunities.
Colloids (Blood Plasma) Market Regional Outlook
North America Colloids (Blood Plasma) Market Analysis
North America accounted for a 38.4% colloids (blood plasma) market share, valued at USD 1.39 billion in 2025. The region's growth is driven by advanced healthcare infrastructure, increasing demand for plasma-derived therapies, rising surgical procedures, and the growing prevalence of chronic and trauma-related conditions requiring volume replacement. Strong investments in healthcare, high plasma collection capacity, and continuous advancements in critical care medicine continue to support regional colloids (blood plasma) market growth.
United States Colloids (Blood Plasma) Market Insights
The United States market accounted for the largest share of the North American market in 2025. Growth is driven by increasing demand for plasma-derived products, expanding hospital and emergency care services, rising surgical procedures, and the presence of leading plasma collection and biopharmaceutical companies. Continuous investment in healthcare innovation further strengthens the country's market position.
Canada Colloids (Blood Plasma) Market Insights
Canada market is witnessing steady market growth due to increasing healthcare expenditure, growing demand for critical care therapies, expanding plasma collection initiatives, and rising adoption of advanced blood management practices across hospitals and healthcare facilities.
Unlock Regional Insights to access country-level data, & regional trends.
Europe Colloids (Blood Plasma) Market Analysis
Europe market accounted for 27.6% of the global colloids (blood plasma) market, reaching USD 1.0 billion in 2025. Market growth is supported by well-established healthcare systems, increasing demand for plasma-derived therapeutics, rising surgical and emergency care procedures, and growing investments in blood transfusion and critical care services. Strong regulatory standards and expanding plasma research continue to drive regional demand.
United Kingdom Colloids (Blood Plasma) Market Insights
The United Kingdom market is witnessing steady market growth owing to increasing demand for plasma-derived medicines, expanding hospital infrastructure, rising surgical volumes, and growing government support for improving blood and plasma collection services.
Germany Colloids (Blood Plasma) Market Insights
Germany market represents one of the largest markets in Europe, driven by its advanced healthcare infrastructure, increasing adoption of plasma-derived therapies, growing investments in biotechnology, and rising demand for critical care and emergency medical treatments.
Asia Pacific Colloids (Blood Plasma) Market Analysis
Asia Pacific market accounted for 22.3% of the global colloids (blood plasma) market, valued at USD 0.81 billion in 2025, and is projected to register the fastest CAGR of 8.12% during the forecast period. The market is expanding due to improving healthcare infrastructure, increasing healthcare expenditure, rising prevalence of chronic diseases, and growing demand for advanced critical care treatments. Expanding plasma collection networks and increasing awareness of plasma-derived therapies continue to support regional market growth.
Japan Colloids (Blood Plasma) Market Insights
Japan market is witnessing steady market growth due to its advanced healthcare system, increasing demand for plasma-derived therapeutics, rising elderly population, and continuous investments in biotechnology and critical care services.
China Colloids (Blood Plasma) Market Insights
China market accounted for the largest share of the Asia Pacific market in 2025. Growth is supported by expanding healthcare infrastructure, increasing plasma collection activities, rising hospital admissions, growing demand for plasma-derived products, and continuous government investments in healthcare modernization.
Middle East & Africa Colloids (Blood Plasma) Market Analysis
The Middle East & Africa market represented 4.9% of the global colloids (blood plasma) market, totaling USD 0.18 billion in 2025. Rising healthcare investments, expanding hospital infrastructure, increasing demand for emergency and critical care services, and improving access to advanced plasma therapies are supporting regional market growth.
UAE Colloids (Blood Plasma) Market Insights
The UAE market is a key market in the Middle East, driven by increasing investments in advanced healthcare facilities, expanding critical care services, rising surgical procedures, and growing adoption of plasma-derived therapies across hospitals.
Africa Colloids (Blood Plasma) Market Insights
The African market is witnessing gradual growth, supported by improving healthcare infrastructure, increasing government investments in blood transfusion services, rising awareness of plasma therapies, and expanding access to emergency medical care. Countries such as South Africa, Egypt, and Kenya are creating long-term growth opportunities for market participants.
List of Key and Emerging Players in Colloids (Blood Plasma) Market
CSL Behring
Baxter
Grifols, S.A.
Octapharma
Shanghai RAAS Blood Products Co. Ltd.
Shandong Taibang Biological Products Co. Ltd (China Biologic Products Inc.)
Hualan Biological Engineering Inc.
Chengdu Rongsheng Pharmaceuticals Co., Ltd. (China National Pharmaceutical Group Corporation)
Adma Biologics Inc.
Key Industry Developments
May 2026: Ingredion entered into a strategic partnership with Sanstar Limited to establish a joint venture focused on specialty ingredients, including pharmaceutical and food ingredient solutions. The collaboration included an equity investment by Ingredion and plans for a jointly owned platform in India to expand specialty ingredient manufacturing capabilities and strengthen formulation solutions across high-value applications.
April 2026: Roquette expanded its healthcare and pharmaceutical ingredient innovation activities by showcasing advanced excipient and formulation solutions. The company continued strengthening its portfolio of specialty ingredients used in pharmaceutical applications, supporting demand for functional colloidal and formulation technologies.
February 2026: Vegan Minerals expanded its international distribution network through a partnership with IMCD India for its WholeCalTM ingredient platform. The collaboration strengthened access to specialty nutrition and ingredient markets in India by combining Vegan Minerals' ingredient technology with IMCD's formulation and distribution capabilities.
January 2026: Aker BioMarine expanded its presence in India through new partnerships, leadership initiatives, and product innovation activities focused on nutrition ingredients. The company introduced new ingredient solutions and strengthened distribution strategies to support growing demand for advanced nutritional formulations.
Report Scope
Comments
No comment